Venus Remedies shares skyrocketed by 8% on 21 December after the company announced that it had received authorization to market its cancer drugs in Israel and Colombia.

In its regulatory filing, the company said that it has received authorization to market three variants of Docetaxel in Israel and Cytarabine 100mg in Colombia.

Docetaxel is a chemotherapy drug that is used in the treatment of different types of cancer, including breast, prostate, stomach, and lung cancers. The Docetaxel variants will be available in 160mg/8ml, 80mg/4ml, 20mg/1ml dosages

Cytarabine is used in the treatment of blood cancers like leukaemia and lymphoma.

In December, the company approved many new products in the Philippines and Saudi Arabia. It has also secured marketing authorization for Zoledronic Acid 4mg and Paclitaxel 100m9/16.7rn1 in the Philippines.

Zoledronic Acid is used for treating many forms of metabolic bone disease, while Paclitaxel is a chemotherapy agent that is used in the treatment of various cancers.

At 3:30 pm, the shares of Venus Remedies closed 6.19% higher at Rs 399.70 on NSE.